Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDDate | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/10/2022 | Q3 2022 | -$0.79 | -$0.84 | -0.05 | N/A | $1.13 M |
08/11/2022 | Q2 2022 | -$0.58 | -$0.89 | -0.31 | N/A | $0 |
05/10/2022 | Q1 2022 | -$0.67 | -$0.58 | 0.09 | N/A | $2.55 M |
03/15/2022 | Q4 2021 | N/A | $0.23 | N/A | N/A | $17.50 M |
11/10/2021 | Q3 2021 | -$0.58 | -$0.52 | 0.06 | N/A | $751,000 |
08/13/2021 | Q2 2021 | N/A | -$0.92 | N/A | N/A | $0 |
05/17/2021 | Q1 2021 | -$1.16 | -$1.08 | 0.08 | N/A | $2.92 M |
03/30/2021 | Q4 2020 | N/A | -$0.50 | N/A | N/A | $163,000 |
11/03/2020 | Q3 2020 | -$1.00 | -$0.38 | 0.62 | N/A | $9.20 M |
08/10/2020 | Q2 2020 | -$1.44 | -$0.71 | 0.73 | N/A | $543,000 |
05/07/2020 | Q1 2020 | -$0.80 | -$0.79 | 0.01 | N/A | $1.36 M |
11/07/2019 | Q3 2019 | -$2.43 | -$0.00 | 2.43 | N/A | $0 |
07/31/2019 | Q2 2019 | -$2.22 | -$0.00 | 2.22 | N/A | $0 |
04/29/2019 | Q1 2019 | -$2.09 | -$0.00 | 2.09 | N/A | $0 |
10/25/2018 | Q3 2018 | -$0.61 | -$0.00 | 0.61 | N/A | $0 |
08/02/2018 | Q2 2018 | N/A | -$0.00 | N/A | N/A | $0 |
04/27/2018 | Q1 2018 | -$0.57 | -$0.00 | 0.57 | N/A | $0 |
10/31/2017 | Q3 2017 | -$0.49 | -$0.00 | 0.49 | N/A | $0 |
07/31/2017 | Q2 2017 | -$0.45 | -$0.00 | 0.45 | N/A | $0 |
04/28/2017 | Q1 2017 | -$0.47 | -$0.00 | 0.47 | N/A | $0 |
F-star Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 8th, 2023 based offlast year's report dates.
In the previous quarter, F-star Therapeutics, Inc. (:FSTX) reported $0.47 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.39 by $0.86.
The conference call for F-star Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for F-star Therapeutics, Inc.'s latest earnings report can be read online.
F-star Therapeutics, Inc. (:FSTX) has a recorded annual revenue of $21.17 M.
F-star Therapeutics, Inc. (:FSTX) has a recorded net income of $-31,283,000.F-star Therapeutics, Inc. has generated $-1.88 earnings per share over the last four quarters.
F-star Therapeutics, Inc. (:FSTX) has a price-to-earnings ratio of -3.79 and price/earnings-to-growth ratio is -0.04.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED